Kirkland & Ellis LLP advised Bristol-Myers Squibb Company (NYSE:BMY), a global biopharmaceutical company, on the sale of its small molecule active pharmaceutical ingredient manufacturing facility in Swords, Ireland, to SK Biotek Co., Ltd. SK Biotek is a rapidly growing contract development and manufacturing organization and a wholly-owned subsidiary of SK Holdings, based in Seoul, South Korea. The Swords facility currently manufactures active pharmaceutical ingredients (APIs) for a number of medicines including Bristol-Myers Squibb’s and Pfizer’s Eliquis. The site has produced medicines that have helped millions of people in the fight against serious diseases such as cancer, cardiovascular disease, hepatitis, HIV/AIDS and psychiatric disorders. Financial terms of the transaction were not disclosed. The transaction is expected to complete by the fourth quarter of 2017. The full release is available here.
The Kirkland team was led by corporate partners Sean Rodgers and Daniel Layfield and associates Daniel Tavakoli and Jonathan Khoury; technology & IP transactions partner Lisa Samenefeld and associate Ashley Eisenberg; environmental transactions partners Brian Land and Stefanie Gitler; and tax partner Sara Zablotney and associate Tristan Evans-Willet.